Breakthru Medicine was founded by oncology drug development veterans who’ve been here before, multiple times. We’ve earned FDA Breakthrough Therapy designations, led multi-billion-dollar acquisitions, and brought transformative cancer therapies to patients worldwide.

We started Breakthru because we saw a better way: combine world-class medicinal chemistry with capital-efficient development, focus on mechanistically validated targets with clear clinical paths, and build programs designed for impact—both for patients and partners. With $60M in Series A funding, we’re advancing multiple programs toward the clinic, applying decades of hard-won lessons to deliver the next generation of precision cancer medicines.